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During the last decade, drug-resistant
Mycobacterium tuberculosis (TB) strains have
emerged,  posing a major threat to global TB
control efforts. The incidence of drug-resistant
TB has increased in many parts of the world, not
only in developing countries but also in
industrialized countries, where the prevalence of
drug-resistant TB had been low (1). The
emergence of drug resistance during antituber-
culosis therapy results mainly from inadequate
therapy, i.e., improper prescription of treatment
regimens, addition of single drugs to failing
treatment regimens, and patient noncompliance.
However, inconsistent drug-susceptibility pat-
terns or delayed responses to TB therapy may
also indicate exogenous reinfection with a strain
resistant to multiple drugs or mixed infection
with a sensitive and a multidrug-resistant TB
strain. Such infections occur in immunocompro-
mised and  immunocompetent persons (2-7) and
may be more common in areas with high
prevalence of resistant TB.
We report the case of an immunocompetent
patient initially infected with an isoniazid- and
streptomycin-resistant TB strain, who after the
first 3 months of TB therapy was found to be
infected with a second multidrug-resistant TB
strain, resulting in treatment failure.  In all,
the patient’s cultures were resistant to nine
anti-TB drugs.
The Study
A 24-year-old man from Kazakhstan was
admitted to hospital A in February 1996, 2 weeks
after his arrival in Germany for further diagnosis
of a cavernous lesion in the upper lobe of his left
lung. The patient reported coughing, but no
weight loss, night sweats, or hemoptysis. An
elevated erythrocyte sedimentation rate was the
only abnormal laboratory finding. He was
seronegative for HIV. A tuberculin skin test was
positive (12 mm), acid-fast bacilli were detected
in gastric aspirates, and two sputum cultures
were positive for TB. Antituberculosis therapy
was started with isoniazid, rifampin, ethambu-
tol, and pyrazinamide. The patient was then
transferred to hospital B, where therapy was
continued with three drugs only (ethambutol was
discontinued). After 2 months of therapy, the
patient showed clinical improvement, resulting
in a sputum smear- and culture-negative phase of
approximately 4 weeks (Table). When suscepti-
bility testing of the first culture obtained 2
months previously revealed resistance to iso-
niazid and streptomycin, ethambutol was re-
added to the treatment regimen. Isolates were
identified as M. tuberculosis complex by using
gene probes (ACCUProbe, GenProbe, San Diego,
California, USA). Drug susceptibility was deter-
mined by the proportion method on Löwenstein-
Jensen medium, the modified proportion method
in BACTEC 460TB, or both.
Suspicion of nonadherence to therapy during
the first 3 months led to transfer of the patient to
hospital C and 3 weeks later to hospital D, where
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Table. Treatment regimens and characteristics of Mycobacterium tuberculosis isolatesa
Susceptibility testing
Current   Time
Therapy Hos- Treatment Cul-  Culture resistance delay Spoli-
(months) pital    regimen ture obtained pattern (months)b gotype
0 A/B H, R, E,c Z pos. 02/28/96 H, S 2 type I
1 B H, R, Z pos. 03/17/96 H, S 2 type I
2 B H, R, E, Z neg.       -  - -   -
3 B H, R, E, Z neg./       - n.d. - n.d.
 pos.
4 C H, E, Pt pos. 06/06/96 H, S, R, (E), (Rb) 2 type II
5 D R, E, Z pos. 07/12/96 H, S, R, (E), (Rb) 2 type II
6 D E, Z, Rb, Of pos.       - n.d. - n.d.
7-12 D E, Z, Rb, Pt pos.       - n.d. - n.d.
13 D E, Z, Rb, Pt pos. 03/15/97 H, S, R, E, Rb, Pt 1 type II
14-18 D Z, Pt, Ci pos. 04/25/97 H, S, R, E, Rb, Pt, Z 5 type II
19 D Z, Pt, Rb, Ci pos.       - n.d. - n.d.
20-21 D Rb, Ci, Am, Pa pos.       - n.d. - n.d.
22-24 D Rb, Ci, Am, Pa, Cl pos.       - n.d. - n.d.
25-28 D Rb, Ci, Am, Pa, Cl pos./ 02/18/98 H, S, R, E, Rb, Pt Z, Pa 4 type II
 neg.
29-32 D Rb, Ci, Am, Pa, Cl pos. 06/23/98 H, S, R, E, Rb, Pt, Z, Pa, Am 4 type II
33 D Rb, Ci, Cl, Ca pos.       - n.d. - n.d.
aAbbreviations and symbols: H, isoniazid; S, streptomycin; R, rifampin; E, ethambutol; Rb, rifabutin; Pt, protionamide; Z,
pyrazinamide; Pa, p=aminosalicylic acid; Am, amikacin; Of, ofloxacin, Ci, ciprofloxacin; Cl, clofazimine; Ca, capreomycin;
borderline results are shown in parentheses; pos., positive culture result; neg., negative culture result; n.d., not determined.
bTime between the date on which the specimen was obtained and the date on which the drug-susceptibility pattern was
available for the clinician (drug-susceptibility tests were not always performed directly after the cultures were grown but were
done retrospectively).
cE was given in the first 4 days of therapy only.
treatment was administered on a closed ward
(Table). At that time, cultures tested positive
again, and the chest X-ray showed slight
deterioration. On August l, 1996,  the latest
susceptibility tests showed resistance to iso-
niazid, rifampin, and streptomycin, and an
intermediate result for rifabutin and ethambutol.
Therapy was switched to ethambutol, pyrazina-
mide, rifabutin, and ofloxacin. Subsequently,
treatment regimens were changed several times,
but cultures continued to be positive for
mycobacteria.  In early 1997, atelectasis of the
left lower lobe and thickening of the wall of the
cavernous lesion in the left upper lobe became
apparent. Lung resection was suggested, but
thoracic surgeons declined to operate because of
the extensive lung involvement. By year-end,
susceptibility tests showed resistance to seven
drugs: isoniazid, rifampin, ethambutol, pyrazina-
mide, protionamide, rifabutin, and streptomycin.
A regimen with rifabutin, ciprofloxacin, amikacin,
para-aminosalicylic acid, and clofazimine led to a
short phase of negative sputum cultures, but a
chest X-ray showed no improvement. Later,
additional resistance to para-aminosalicylic acid
and amikacin was documented.
To elucidate the reasons for therapy failure,
we compared the current susceptibility patterns
with the treatment regimens applied earlier. We
found that during several phases of treatment,
this patient was treated with only one effective
drug. During extended periods, he was culture
positive, but no susceptibility tests were
performed, even after relapse. Additionally,
treatment regimens were changed, and single
drugs were added several times without
determination of the actual resistance pattern.
Treatment regimens, drug-susceptibility pat-
terns, and detailed information on the history of
the case are summarized in the Table.
All isolates obtained were submitted to
spoligotyping and IS6110 fingerprinting (5,8).
Spoligotypes (Figure), as well as the IS6110
restriction fragment length polymorphism (RFLP)
patterns (data not shown) of the first two
isoniazid- and streptomycin-resistant cultures,
were identical (type I) but differed clearly
(IS6110 identity of less than 30%) from those of550 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
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Figure. Spoligotypes and drug-resistance patterns of isolates of patient’s first (1 and 2, type I) and second culture-
positive phase (3-8, type II). The spoligotypes of the first two cultures differ clearly from those of the latter ones.
The eight isolates were obtained on the following dates: 1, February 28, 1996;  2, March 17, 1996; 3, June 6, 1996;
4, July 12, 1996;  5, March 15, 1997; 6, April 25, 1997;  7, February 18, 1998; and 8, June 23, 1998. H, isoniazid;
S, streptomycin; R, rifampin; E, ethambutol; Rb, rifabutin; Pt, protionamide; Z, pyrazinamide; Pa,
p=aminosalicylic acid; Am, amikacin.  Borderline results are displayed in parentheses.
later multidrug-resistant isolates (second phase
of sputum culture positivity, type II; see Table).
These results indicate that the patient was
infected with a second TB strain, which showed
initial resistance to isoniazid, streptomycin, and
rifampin, and borderline resistance to ethambu-
tol and rifabutin. IS6110 RFLP patterns of
multidrug-resistant isolates from the patient
were compared with those from other patients
who had been treated in hospitals B and C during
the same period and with IS6110  RFLP patterns
from resistant TB strains isolated from unrelated
patients living in other areas of Germany.
Gelcompar software was used for this analysis
(Windows 95, version 4.0; Applied Maths,
Kortrijk, Belgium) (5). No isolate showing an
identical IS6110 RFLP pattern was identified
(data not shown). Spoligotype and the IS6110
RFLP patterns of the patient’s multidrug-
resistant strain were similar to those of the W-
strain or Beijing family, which have been found in
New York, USA, and Beijing, China (9,10).
Conclusions
We report an immunocompetent patient with
pulmonary TB who had double infection with a
resistant and a multidrug-resistant TB strain,
leading to therapy failure. After 2 years of
treatment, resistance to eight antituberculosis
drugs—including the most potent first- and
second-line treatments—occurred, despite clini-
cally supervised hospital therapy. Four months
later, resistance to a ninth drug occurred.
Progressive disease caused by a second multidrug-
resistant TB strain, as demonstrated by
molecular strain typing methods, was the initial
cause for this occurrence. A possible variation of
the initial strain has been excluded since the
spoligotype patterns of the multidrug-resistant
isolates completely differed from the two isolates
of the first TB period (spoligotype patterns have
been shown to be highly stable among serial
patient isolates [11]).
In this case, TB therapy was often based on
drug-resistance data not representing the
current drug-resistance pattern, resulting in
improper treatment and many periods in which
the patient received only one effective drug;  the
second TB strain could have acquired further
resistance during these many periods of
monotherapy. Earlier identification of the second
infection might have led to treatment with a more
appropriate drug regimen, resulting in a more
successful outcome. The second multidrug-
resistant TB strain could have been acquired by
mixed-strain  infection or exogenous reinfection
(2-7). However, our investigation did not  identify
a possible index patient. Moreover, the fact that
the patient was an immigrant from Kazakhstan,
a country with high rates of resistant TB (1),
suggests that he may have been infected with
the second multidrug-resistant strain in his
homeland.
This patient was seronegative for HIV and
had no clinical measurements indicative of
immunosuppression, suggesting that additionalVol. 6, No. 5, September–October 2000 Emerging Infectious Diseases 551
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infection with multidrug-resistant TB during
treatment can be largely independent of a host’s
immune status.  These  mixed-strain infections
with at least one resistant strain may lead to
unsuccessful TB therapy.  Although few have
been reported (6, 7), such cases may become  more
frequent in areas with high rates of drug-
resistant TB. Standard TB treatment apparently
is not sufficient to protect patients from infection
with a second multidrug-resistant TB strain.
Clinicians should consider the possibility of
additional infection with multidrug-resistant TB
in cases when TB therapy fails. In such cases,
inappropriate treatment regimens and delayed
follow-up of susceptibility tests can permit
additional resistance to develop, which can
dramatically complicate TB therapy. However,
regardless of the cause, when a clinical course is
abnormal, adding single drugs to failing
treatment regimens should be avoided, and
retreatment programs should not be initiated
before culture sensitivity results are available.
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